We use cookies to help provide you with the best possible online experience. Learn more

    Year-end Report January 1 - December 31, 2017

    PDF

    RaySearch Laboratories AB (publ)

    “In 2017, net sales rose 10 percent to SEK 585 M (531). The operating margin declined to 27 percent (38) due to lower growth for RayStation®, negative currency effects due to the weakening of the USD and higher costs due to the company’s investments in the global marketing organization and in research and development. RayStation 7 and RayCare® 1 were launched as planned and we have already secured the first order for RayCare,” says Johan Löf, President and CEO of RaySearch.

    FOURTH QUARTER (OCTOBER-DECEMBER 2017) 

    • Net sales SEK 204.9 M (191.4), of which revenues from RayStation/RayCare SEK 192.6 M (174.8)  
    • Profit after tax SEK 72.3 M (75.9) and earnings per share before/after dilution SEK 2.11 (2.21) 
    • Operating profit SEK 98.7 M (100.2) 
    • Cash flow SEK 34.6 M (56.6) 
    • Order intake excl. service agreements SEK 192.6 M (189.0), of which RayStation/RayCare SEK 183.2 M (176.3)  
    • Order backlog for RayStation/RayCare was SEK 50.0 M (67.6) at the end of the period

    TWELVE MONTHS (JANUARY-DECEMBER 2017) 

    • Net sales SEK 585.1 M (531.5), of which revenues from RayStation/RayCare SEK 531.7 M (476.0)  
    • Profit after tax SEK 117.6 M (151.4) and earnings per share SEK 3.43 (4.42) 
    • Operating profit SEK 159.7 M (200.0) 
    • Cash flow SEK 19.1 M (26.2) 
    • Order intake excl. service agreements SEK 508.4 M (501.1), of which RayStation/RayCare SEK 467.8 M (461.0)  
    • The Board of Directors proposes that no dividend be paid for 2017

    SIGNIFICANT EVENTS DURING THE FOURTH QUARTER 

    • RayStation was selected by a number of leading cancer clinics, for example, Sharp Grossmont Hospital, Anderson Regional Cancer Center and Erlanger Hospital in the US, Hôtel-Dieu de Lévis in Canada, Lausanne University Hospital (CHUV) in Switzerland, Centre Francois Baclesse in Luxemburg, Charing Cross Hospital and Hammersmith Hospital in the UK, and Maria Sklodowska-Curie Memorial Cancer Center in Poland. In addition, RayStation was also selected for a new carbon ion center at the Yamagata University Hospital in Japan and for the Apollo Proton Cancer Center in Chennai, which is the first proton therapy center in India. 
    • RayStation 7* was released with support for Mevion HYPERSCAN and integration with RayCare. RaySearch also launched µ-RayStation, a new version of the treatment planning system, which is specially adapted for pre-clinical research on small animals. 
    • RayCare 1, the next-generation oncology information system (OIS), was released as planned and the company has secured the first order for RayCare from Anderson Regional Cancer Center in the US.
          

    NO SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD 

    The information contained in the interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on February 15, 2018 at 7:45 a.m. CET.
       

    FOR FURTHER INFORMATION, PLEASE CONTACT:
    Johan Löf, President and CEO    Tel: +46 8 510 530 00     E-mail: johan.lof@raysearchlabs.com
    Peter Thysell, CFO    Tel: +46 70 661 05 59     E-mail:
    peter.thysell@raysearchlabs.com
      

    ABOUT RAYSEARCH
    RaySearch Laboratories AB (publ) is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. The company develops and markets the RayStation treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which was launched in December 2017 and comprises a new product area for RaySearch. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
    More information about RaySearch is available at
    www.raysearchlabs.com.

    * Regulatory approval is required in some markets.

    PDF

    Year-end Report January 1 - December 31, 2017

    PDF

    RaySearch Laboratories AB (publ)

    “In 2017, net sales rose 10 percent to SEK 585 M (531). The operating margin declined to 27 percent (38) due to lower growth for RayStation®, negative currency effects due to the weakening of the USD and higher costs due to the company’s investments in the global marketing organization and in research and development. RayStation 7 and RayCare® 1 were launched as planned and we have already secured the first order for RayCare,” says Johan Löf, President and CEO of RaySearch

    FOURTH QUARTER (OCTOBER-DECEMBER 2017) 

    • Net sales SEK 204.9 M (191.4), of which revenues from RayStation/RayCare SEK 192.6 M (174.8)  
    • Profit after tax SEK 72.3 M (75.9) and earnings per share before/after dilution SEK 2.11 (2.21) 
    • Operating profit SEK 98.7 M (100.2) 
    • Cash flow SEK 34.6 M (56.6) 
    • Order intake excl. service agreements SEK 192.6 M (189.0), of which RayStation/RayCare SEK 183.2 M (176.3)  
    • Order backlog for RayStation/RayCare was SEK 50.0 M (67.6) at the end of the period

    TWELVE MONTHS (JANUARY-DECEMBER 2017) 

    • Net sales SEK 585.1 M (531.5), of which revenues from RayStation/RayCare SEK 531.7 M (476.0)  
    • Profit after tax SEK 117.6 M (151.4) and earnings per share SEK 3.43 (4.42) 
    • Operating profit SEK 159.7 M (200.0) 
    • Cash flow SEK 19.1 M (26.2) 
    • Order intake excl. service agreements SEK 508.4 M (501.1), of which RayStation/RayCare SEK 467.8 M (461.0)  
    • The Board of Directors proposes that no dividend be paid for 2017

    SIGNIFICANT EVENTS DURING THE FOURTH QUARTER 

    • RayStation was selected by a number of leading cancer clinics, for example, Sharp Grossmont Hospital, Anderson Regional Cancer Center and Erlanger Hospital in the US, Hôtel-Dieu de Lévis in Canada, Lausanne University Hospital (CHUV) in Switzerland, Centre Francois Baclesse in Luxemburg, Charing Cross Hospital and Hammersmith Hospital in the UK, and Maria Sklodowska-Curie Memorial Cancer Center in Poland. In addition, RayStation was also selected for a new carbon ion center at the Yamagata University Hospital in Japan and for the Apollo Proton Cancer Center in Chennai, which is the first proton therapy center in India. 
    • RayStation 7* was released with support for Mevion HYPERSCAN and integration with RayCare. RaySearch also launched µ-RayStation, a new version of the treatment planning system, which is specially adapted for pre-clinical research on small animals.  
    • RayCare 1, the next-generation oncology information system (OIS), was released as planned and the company has secured the first order for RayCare from Anderson Regional Cancer Center in the US
         

    NO SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD 

    The information contained in the interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on February 15, 2018 at 7:45 a.m. CET.
       

    FOR FURTHER INFORMATION, PLEASE CONTACT:
    Johan Löf, President and CEO    Tel: +46 8 510 530 00     E-mail: johan.lof@raysearchlabs.com
    Peter Thysell, CFO    Tel: +46 70 661 05 59     E-mail:
    peter.thysell@raysearchlabs.com
      

    ABOUT RAYSEARCH
    RaySearch Laboratories AB (publ) is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. The company develops and markets the RayStation treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which was launched in December 2017 and comprises a new product area for RaySearch. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
    More information about RaySearch is available at www.raysearchlabs.com.
      

    * Regulatory approval is required in some markets.

    PDF

    Mitchell Cancer Institute, US, selects RayStation for TomoTherapy

    PDF

    The University of South Alabama Mitchell Cancer Institute (MCI) in Mobile, Alabama, has selected RayStation* as its treatment planning system for the TomoTherapy ® System. The center also treats patients using a CyberKnife ®System and will use RayStation* for this in the future.

    MCI’s radiation therapy service is equipped with state-of-the-art Accuray´s CyberKnife and TomoTherapy System, as well as a 64-slice PET-CT scanner. The center was initially interested in RayStation’s forthcoming support for the CyberKnife System, but quickly saw that the system could meet all of its treatment planning needs into the future, including the TomoTherapy System.

    Dr. Weisi Yan, Director of the CyberKnife Program at MCI, says: “We were very impressed by the capabilities and user-friendliness of RayStation. As a leading-edge treatment center, we need the best possible technology in order to deliver outstanding care and maximize efficiency. RayStation will help us to achieve our goals.”

    Hal Hopper, Manager of MCI’s Department of Radiation Oncology, says: “RayStation is fast and effective in planning treatments for all possible techniques we are likely to offer. It is much less labor-intensive than other systems we have used. With RayStation, the physician can choose the best course of treatment more quickly.”

    Johan Löf, CEO of RaySearch, says: “MCI shares our vision of continuously advancing cancer treatment. We are very pleased to be able to meet their requirements for advanced clinical techniques as well as optimized workflows and use of resources.”
        

    About MCI
    Founded in 2000, MCI provides cancer treatment in three locations: MCI headquarters in Mobile, the MCI Kilborn Clinic in Fairhope and Monroe County Hospital in Monroeville. The center’s researchers and clinicians focus daily on the battle against cancer serving a potential catchment population of more 4.1 million people, with a singular focus of advancing cancer diagnosis, treatment and prevention in the region and beyond. Since its establishment, the center’s strategic goal has remained constant: to achieve competitiveness for future designation as an NCI Comprehensive Cancer Center and to achieve self-sustaining, long-term financial viability.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy*. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com 

    PDF

    RayStation selected for India’s first Proton Center

    PDF

    Apollo Hospitals, Asia´s foremost integrated healthcare provider, as selected RayStation for a new proton therapy center in Chennai – the first such facility in India. The center will be equipped with IBA’s Proteus®PLUS treatment delivery system in a multi-room configuration. The setup will comprise two gantry treatment rooms and one fixed-beam treatment room, each fitted with advanced pencil beam scanning and cone beam CT technology.

    Following an extensive review of the leading systems available, RayStation was selected as the treatment planning system for the new center, which is scheduled to treat its first patients in September 2018. The choice was motivated by RayStation’s comprehensive functionality and support for all major treatment delivery systems, and RaySearch’s world-leading position in proton therapy treatment planning. An important goal for Apollo Hospitals is to unify the treatment planning workflow. The agreement includes modules for deformable registration, dose tracking, adaptive therapy and multi-criteria optimization.

    Preetha Reddy, Vice Chairperson, Apollo Hospitals Groups says: “Our resolute commitment is to make cancer conquerable and the Apollo Proton Cancer Center in Chennai underscores this etos. Over the years, we have continuously introduced the most advanced cancer care for our patients and Apollo has been honored with the trust of individuals from over 140 countries.”
    Ms. Reddy added, “Innovative technologies have been a hallmark of our cancer care protocols with RayStation reaffirms our continued investments into the best available care for modalities for our patients.”

    Johan Löf, CEO of RaySearch, says: “We are delighted to have been chosen by Apollo Hospitals for their ground-breaking introduction of proton therapy in India. Apollo shares our view of the many benefits in having a single treatment planning system for all treatment machines, and our partnership will result in high efficiency and outstanding patient care. This installation reinforces our strong and growing presence in the APAC region and our commitment to supporting the widest possible range of treatment machines.”

         

    About Apollo Hospitals
    Apollo Hospitals is widely recognized as a pioneer of private healthcare in India and established the country’s first corporate hospital in 1983. Today, it is one of Asia’s foremost integrated healthcare services providers, operating 64 hospitals as well as pharmacies, primary care and diagnostic clinics.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton and carbon ion therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com

    PDF

    Beaumont Hospital, US, extends RayStation to Photon Therapy

    PDF

    Beaumont Hospital in Royal Oak, Michigan, has chosen to make a significant extension to its RayStation installation, which will include photon therapy in addition to proton. RayStation will be used for photon planning at Beaumont Hospital in Dearborn, where new linacs will be commissioned for the system. The purchase also includes additional functionality and licenses for proton therapy at Beaumont Hospital, Royal Oak.

    The nationally recognized cancer program at Beaumont is based on the latest treatment technologies. Beaumont initially purchased RayStation for proton therapy in 2014, and advanced features such as adaptive therapy and deformable registration are key elements of its workflow.

    “We are excited about having the opportunity to extend RayStation to our photon business,” says Craig Stevens, M.D., Ph.D., Radiation Oncologist and Chairman, Radiation Oncology at Beaumont. “It will allow us to mix proton and photon planning, ultimately streamlining and improving efficiency.”

    Xuanfeng Ding, Ph.D., Lead Proton Physicist, adds: “We often create both a photon and proton plan and compare side-by-side to determine the best treatment option for each patient. Deformable registration has been a great help in our proton center, helping us to evaluate previous dose and generate the plan sum on the current CT. In combination with the adaptive functionality, it definitely helps improves quality of patient care and workflow efficiency.

    Johan Löf, CEO of RaySearch, says: “Beaumont has an outstanding track record in using advanced technology to ensure the optimal treatment method for each patient. RayStation is an excellent fit for this approach, with comprehensive functionality to support cutting-edge techniques and the widest range of treatment machines. I look forward to a successful partnership that will benefit many patients in Michigan.”
     

    About Beaumont Hopsital
    Beaumont is Michigan’s largest healthcare system, established in 2014 to provide patients in Southeast Michigan with compassionate, extraordinary care. Beaumont Health’s culture of caring partnerships and its care delivery model of patient- and family-centered care demonstrates its commitment to engaging patients, families and the community to promote continuous healthcare improvements. With 8 hospitals, 174 health centers, close to 5,000 physicians and 38,000 employees, Beaumont Health contributes to the health and well-being of residents throughout Southeast Michigan and beyond.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton and carbon ion therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
     

    To learn more about RaySearch, go to: www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com

    PDF

    RayStation selected for Charing Cross Hospital and Hammersmith Hospital in London

    PDF

    Imperial College Healthcare NHS Trust in London, UK, has chosen RayStation as the sole treatment planning system for two sites in London: Charing Cross Hospital and Hammersmith Hospital. RayStation was selected as the best solution following a thorough evaluation of all potential treatment planning systems on the market.

    The Imperial College Healthcare NHS Trust operates five hospitals in London, plus a range of community health services. Its radiation therapy services are provided at Charing Cross Hospital and Hammersmith Hospital. RayStation will replace two different treatment planning systems currently in use at the hospitals.

    The two hospitals will use RayStation for all radiation therapy treatment planning activities, as well as all pre-treatment virtual simulation. RayStation will replace the hospitals’ current standalone system for virtual simulation. The purchase comprises a broad range of functionality, including 3D-CRT, IMRT, VMAT, multi-criteria optimization, automated breast planning and adaptive planning.

    Johan Löf, CEO of RaySearch, says: “We are very pleased to support the needs of these two leading London hospitals. The aim with RayStation is to provide the most comprehensive functionality. This makes it possible for clinics to consolidate multiple systems, increase efficiency and reduce the need for staff training. We look forward to a successful partnership.”

    About Imperial College Healthcare NHS Trust
    Imperial College Healthcare NHS Trust provides acute and specialist healthcare for a population of nearly two million people in north west London, and more beyond. The Trust has five hospitals in London – Charing Cross, Hammersmith, Queen Charlotte’s & Chelsea, St Mary’s and The Western Eye – and runs a growing number of community services. With its academic partner, Imperial College London, the trust is one of the UK’s 11 academic health science centres, working to ensure the rapid translation of research for better patient care and excellence in education.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy*. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
      

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com

    PDF

    RaySearch receives first order for the RayCare™ Oncology infomation System

    PDF

    Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, USA, has placed the first order for RayCare*, a next-generation oncology information system (OIS). RayCare is an innovative system designed to support comprehensive cancer care. It integrates seamlessly with the RayStation treatment planning system, but that’s just the start – RayCare will connect all the oncology disciplines, enabling users to fluidly coordinate tasks and ensure optimal use of resources.

    Over subsequent releases, RayCare will evolve into a machine learning OIS with unique capabilities to coordinate oncology tasks, supporting comprehensive cancer care organized around each patient’s needs. Many cancer patients receive a combination of treatment types, driving the need for combined workflows for radiation therapy, chemotherapy and surgery.

    ARCC decided to map out a future for their clinical workflows that would support advanced technology and data driven decision making. They determined that the best approach would be to move to a new treatment planning system and a new oncology information system that together would support their linacs and TomoTherapy systems, in order to have a unified platform for planning, treatment and assessment.

    Paul King, Chief Medical Physicist, says: “We evaluated all the leading systems and were extremely impressed by the possibilities of RayCare. It delivers on everything we were looking for. Getting all of these pieces integrated together will help us tremendously. RaySearch is an innovator with the leading technology in this area and I have great confidence in their ability to meet our needs into the future. We will keep exploring the cutting-edge of technology in order to secure the best possible care for our patients. RayCare will help us achieve this aim.”

    Dr. Scott Anderson, Radiation Oncologist and Medical Director, says: “We find ourselves in the position that we are at a decision point where we can stay static in a satisfactory status quo, or we can move into what will be the standard in the future. We look forward to working with RaySearch Laboratories to shape the future of longitudinal cancer care. Survivorship and tracking patients long term will be the benchmarks of cancer care moving forward. This new system that is being developed will give us better tools to do so.”

    Johan Löf, CEO of RaySearch, says: “I am delighted by this first RayCare order and very excited about helping ARCC achieve an efficient, integrated system for the future. RayCare is fundamentally different compared to other OIS systems, and we have invested a great deal of time and effort into creating something that will truly change the way that cancer is treated. Our goal is to advance cancer treatment with high-performance tools that combine treatment planning, workflow and data management, resource optimization, machine learning and follow-up in an effective way.”

    About Anderson Regional Cancer Center
    Anderson Regional Cancer Center in Meridian, Mississippi, is a state-of-the-art cancer center equipped to provide innovative treatment for all types of cancer. The center sees about 180 outpatients a day for radiation or chemotherapy treatments and serves a geographical area across East Mississippi and West Alabama.

    About RayCare
    RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.


    To learn more about RaySearch, go to:
    www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com
     

    PDF

    RayStation selected for new Carbon ion therapy center in Japan

    PDF

    RayStation* has been chosen as the treatment planning system for a new carbon-ion therapy facility which is under construction at Yamagata University Hospital in northern Japan. The order represents the first RayStation carbon ion installation in Japan.

    Carbon ion therapy is an advanced form of radiation therapy that precisely targets cancer cells with minimal damage to surrounding tissue. The technique uses a carbon ion beam, accelerated up to 70% of the speed of light. Carbon ion beams are highly effective in destroying cancer cells, and the technique can be effective for cancers that are resistant to X-rays. An additional advantage is that the treatment period often is shorter than for other forms of radiation therapy.

    RayStation was selected jointly by Yamagata University Hospital and Toshiba, which is supplying the treatment delivery system. The decision was motivated by RayStation’s outstanding functionality and comprehensive support for this cutting-edge treatment technique. The RayStation installation will include modules for carbon pencil beam scanning with robust biological optimization (using both the MKM and LEM models), deformable registration, dose tracking and adaptive therapy.

    The facility expects to treat its first patients by early 2020. Toshiba’s treatment delivery system will comprise two treatment rooms, a fixed-port room and a 360-degree rotating compact superconducting gantry. The facility will be the most compact carbon ion installation in the world, and one of the few integrated into a general hospital.

    Johan Löf, CEO of RaySearch, says: “RaySearch is committed to providing the leading support for cutting-edge techniques such as carbon ion therapy, and we are very pleased to meet the needs of Yamagata University Hospital and Toshiba. RayStation has a strong and growing user base in Japan, and we will continue to focus resources on this technologically advanced market.”
      

    About Yamagata University Hospital
    Yamagata University Hospital is a major general hospital located in Yamagata prefecture, northern Japan. Established in 1976, the hospital offers a wide range of medical specialties, including oncology. The hospital’s clinical cancer center was established in 2007. Yamagata University Hospital works to pursue its philosophy of “deeply humane and reliable medical care.”

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy*. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.
     

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com

    PDF